These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25754231)

  • 1. Synthesis of bis-macrocyclic HCV protease inhibitor MK-6325 via intramolecular sp²-sp³ Suzuki-Miyaura coupling and ring closing metathesis.
    Li H; Scott JP; Chen CY; Journet M; Belyk K; Balsells J; Kosjek B; Baxter CA; Stewart GW; Wise C; Alam M; Song ZJ; Tan L
    Org Lett; 2015 Mar; 17(6):1533-6. PubMed ID: 25754231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a practical, asymmetric synthesis of the hepatitis C virus protease inhibitor MK-5172.
    Kuethe J; Zhong YL; Yasuda N; Beutner G; Linn K; Kim M; Marcune B; Dreher SD; Humphrey G; Pei T
    Org Lett; 2013 Aug; 15(16):4174-7. PubMed ID: 23919347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans.
    Faucher AM; Bailey MD; Beaulieu PL; Brochu C; Duceppe JS; Ferland JM; Ghiro E; Gorys V; Halmos T; Kawai SH; Poirier M; Simoneau B; Tsantrizos YS; Llinàs-Brunet M
    Org Lett; 2004 Aug; 6(17):2901-4. PubMed ID: 15330643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient large-scale synthesis of BILN 2061, a potent HCV protease inhibitor, by a convergent approach based on ring-closing metathesis.
    Yee NK; Farina V; Houpis IN; Haddad N; Frutos RP; Gallou F; Wang XJ; Wei X; Simpson RD; Feng X; Fuchs V; Xu Y; Tan J; Zhang L; Xu J; Smith-Keenan LL; Vitous J; Ridges MD; Spinelli EM; Johnson M; Donsbach K; Nicola T; Brenner M; Winter E; Kreye P; Samstag W
    J Org Chem; 2006 Sep; 71(19):7133-45. PubMed ID: 16958506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bismacrocyclic inhibitors of hepatitis C NS3/4a protease.
    McCauley JA; Rudd MT; Nguyen KT; McIntyre CJ; Romano JJ; Bush KJ; Varga SL; Ross CW; Carroll SS; DiMuzio J; Stahlhut MW; Olsen DB; Lyle TA; Vacca JP; Liverton NJ
    Angew Chem Int Ed Engl; 2008; 47(47):9104-7. PubMed ID: 18925594
    [No Abstract]   [Full Text] [Related]  

  • 6. Novel macrocyclic HCV NS3 protease inhibitors derived from α-amino cyclic boronates.
    Li X; Zhang YK; Liu Y; Ding CZ; Zhou Y; Li Q; Plattner JJ; Baker SJ; Zhang S; Kazmierski WM; Wright LL; Smith GK; Grimes RM; Crosby RM; Creech KL; Carballo LH; Slater MJ; Jarvest RL; Thommes P; Hubbard JA; Convery MA; Nassau PM; McDowell W; Skarzynski TJ; Qian X; Fan D; Liao L; Ni ZJ; Pennicott LE; Zou W; Wright J
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5695-700. PubMed ID: 20801653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, antiviral activity, and conformational studies of a P3 aza-peptide analog of a potent macrocyclic tripeptide HCV protease inhibitor.
    Randolph JT; Zhang X; Huang PP; Klein LL; Kurtz KA; Konstantinidis AK; He W; Kati WM; Kempf DJ
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2745-50. PubMed ID: 18375121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A highly convergent and efficient synthesis of a macrocyclic hepatitis C virus protease inhibitor BI 201302.
    Wei X; Shu C; Haddad N; Zeng X; Patel ND; Tan Z; Liu J; Lee H; Shen S; Campbell S; Varsolona RJ; Busacca CA; Hossain A; Yee NK; Senanayake CH
    Org Lett; 2013 Mar; 15(5):1016-9. PubMed ID: 23406520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
    Ding CZ; Zhang YK; Li X; Liu Y; Zhang S; Zhou Y; Plattner JJ; Baker SJ; Liu L; Duan M; Jarvest RL; Ji J; Kazmierski WM; Tallant MD; Wright LL; Smith GK; Crosby RM; Wang AA; Ni ZJ; Zou W; Wright J
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7317-22. PubMed ID: 21067923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of the HCV protease inhibitor Vaniprevir (MK-7009) using ring-closing metathesis strategy.
    Kong J; Chen CY; Balsells-Padros J; Cao Y; Dunn RF; Dolman SJ; Janey J; Li H; Zacuto MJ
    J Org Chem; 2012 Apr; 77(8):3820-8. PubMed ID: 22458448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vinylated linear P2 pyrimidinyloxyphenylglycine based inhibitors of the HCV NS3/4A protease and corresponding macrocycles.
    Lampa A; Alogheli H; Ehrenberg AE; Åkerblom E; Svensson R; Artursson P; Danielson UH; Karlén A; Sandström A
    Bioorg Med Chem; 2014 Dec; 22(23):6595-6615. PubMed ID: 25456385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
    Venkatraman S; Njoroge FG; Girijavallabhan VM; Madison VS; Yao NH; Prongay AJ; Butkiewicz N; Pichardo J
    J Med Chem; 2005 Aug; 48(16):5088-91. PubMed ID: 16078825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV.
    Ersmark K; Nervall M; Gutiérrez-de-Terán H; Hamelink E; Janka LK; Clemente JC; Dunn BM; Gogoll A; Samuelsson B; Qvist J; Hallberg A
    Bioorg Med Chem; 2006 Apr; 14(7):2197-208. PubMed ID: 16307884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P2-P1' macrocyclization of P2 phenylglycine based HCV NS3 protease inhibitors using ring-closing metathesis.
    Lampa A; Ehrenberg AE; Vema A; Åkerblom E; Lindeberg G; Danielson UH; Karlén A; Sandström A
    Bioorg Med Chem; 2011 Aug; 19(16):4917-27. PubMed ID: 21782454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of potent macrocyclic HCV NS5A inhibitors.
    Yu W; Vibulbhan B; Rosenblum SB; Martin GS; Vellekoop AS; Holst CL; Coburn CA; Wong M; Selyutin O; Ji T; Zhong B; Hu B; Chen L; Dwyer MP; Jiang Y; Nair AG; Tong L; Zeng Q; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Fells J; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3793-9. PubMed ID: 27282743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological activity of macrocyclic inhibitors of hepatitis C virus (HCV) NS3 protease.
    Chen KX; Njoroge FG; Prongay A; Pichardo J; Madison V; Girijavallabhan V
    Bioorg Med Chem Lett; 2005 Oct; 15(20):4475-8. PubMed ID: 16112859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Synthesis of a Spirocyclic Macrocyclic Protease Inhibitor for the Treatment of Hepatitis C.
    Chung CK; Cleator E; Dumas AM; Hicks JD; Humphrey GR; Maligres PE; Nolting AF; Rivera N; Ruck RT; Shevlin M
    Org Lett; 2016 Mar; 18(6):1394-7. PubMed ID: 26950496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease.
    Rudd MT; McCauley JA; Romano JJ; Butcher JW; Bush K; McIntyre CJ; Nguyen KT; Gilbert KF; Lyle TA; Holloway MK; Wan BL; Vacca JP; Summa V; Harper S; Rowley M; Carroll SS; Burlein C; DiMuzio JM; Gates A; Graham DJ; Huang Q; Ludmerer SW; McClain S; McHale C; Stahlhut M; Fandozzi C; Taylor A; Trainor N; Olsen DB; Liverton NJ
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7201-6. PubMed ID: 23021993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkers.
    Rudd MT; McIntyre CJ; Romano JJ; Butcher JW; Holloway MK; Bush K; Nguyen KT; Gilbert KF; Lyle TA; Liverton NJ; Wan BL; Summa V; Harper S; Rowley M; Vacca JP; Carroll SS; Burlein C; DiMuzio JM; Gates A; Graham DJ; Huang Q; Ludmerer SW; McClain S; McHale C; Stahlhut M; Fandozzi C; Taylor A; Trainor N; Olsen DB; McCauley JA
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7207-13. PubMed ID: 23084906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diversity-oriented approach to macrocyclic cyclophane derivatives by Suzuki-Miyaura cross-coupling and olefin metathesis as key steps.
    Kotha S; Chavan AS; Shaikh M
    J Org Chem; 2012 Jan; 77(1):482-9. PubMed ID: 22129223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.